Tauroursodeoxycholic Acid (TUDCA)

Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA) and acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases, including AD, Parkinson's diseases (PD), and Huntington's diseases (HD).

Tauroursodeoxycholic Acid (TUDCA) Chemical Structure

Tauroursodeoxycholic Acid (TUDCA) Chemical Structure

CAS: 14605-22-2

Selleck's Tauroursodeoxycholic Acid (TUDCA) has been cited by 30 publications

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Tauroursodeoxycholic Acid (TUDCA) Related Products

Choose Selective Apoptosis related Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells Function assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay, EC50=30 μM 18307294
Sf9 Function assay TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells, Km=4.1μM 10648470
MDCK Function assay TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells, Km=6.6μM 11093941
HEK293 Function assay 90 mins Inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in choline release from LPC measured every 30 secs for 90 mins by HVA based fluorescence assay, IC50=10.3μM 28165241
Sf9 Function assay TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells, Km=11.9μM 12404240
CHO Function assay TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells, Km=14μM 9486191
COS Function assay TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells, Ki=28μM 9458785
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of CHOP mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as reduction in XBPs/XBPu ratio after 6 hrs 27729186
HuH7 Cytoprotective assay 1 mM 24 hrs Cytoprotective activity against DCA-induced cell death in human HuH7 cells assessed as increase in cell viability at 1 mM preincubated with cells followed by DCA addition measured after 24 hrs by MTT/INCELL assay 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of BIP/GRP78 mRNA levels after 6 hrs 27729186
HEK293 Function assay Non-competitive inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in LPC hydrolysis by Lineweaver-Burk plot analysis 28165241
Click to View More Cell Line Experimental Data

Biological Activity

Description Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA) and acts as a mitochondrial stabilizer and anti-apoptotic agent in several models of neurodegenerative diseases, including AD, Parkinson's diseases (PD), and Huntington's diseases (HD).
In vitro
In vitro Tauroursodeoxycholic acid (TUDCA) is an endogenous hydrophilic tertiary bile acid produces in humans at a low level. In ER stress conditions, TUDCA treatment of MSCs (mesenchymal stem cells) reduces the activation of ER stress-associated proteins, including GRP78, PERK, eIF2α, ATF4, IRE1α, JNK, p38, and CHOP, and inhibits the dissociation between GRP78 and PERK, resulting in reduced ER stress-mediated cell death. TUDCA treatment increases PrPC (Cellular prion protein) expression. TUDCA regulates stem cell differentiation into various lineages such as adipogenic and osteogenic lineages. TUDCA attenuates ER stress, prevents unfolded protein response dysfunction, and stabilizes mitochondria. Under ER stress, treatment with TUDCA significantly increases the expression of BCL-2 and significantly decreases the expression of Bax, cleaved caspase-3, and cleaved PARP-1, compared with that of untreated cells[1].
Cell Research Cell lines Mesenchymal stem cells (MSCs)
Concentrations 100 μM
Incubation Time 30 min
Method

MSCs are washed twice with phosphate buffer saline (PBS), and fresh α-MEM supplemented with 10% FBS is added. To investigate the apoptosis signaling pathway, MSCs are pretreated with TUDCA (100 μM) at 37 °C for 30 min and then treated with H2O2 (200 μM) for various times (0, 2, 4, 6, or 8 h). To assess another cell signaling pathway, MSCs are treated with an Akt inhibitor (10−6 M) for 30 min at 37 °C before treatment with TUDCA.

Experimental Result Images Methods Biomarkers Images PMID
Western blot p-Akt / Akt PrPc CHOP / Caspase-12 / Cleaved caspase-12 RIPK1 / RIPK3 / p-RIPK1 / p-RIPK3 28004805
Growth inhibition assay Cell viability 30038553
In Vivo
In vivo TUDCA is effective for treating cholestatic liver diseases. It also has an ameliorating effect on several diseases, including neurodegenerative diseases, osteoarthritis, vascular diseases, and diabetes. In a murine hindlimb ischemia model, TUDCA-treated mesenchymal stem cells (MSCs) transplantation augments the blood perfusion ratio, vessel formation, and transplanted cell survival more than untreated MSC transplantation does. Augmented functional recovery following MSC transplantation is blocked by PrPC downregulation[1]. Several studies in animals have shown that TUDCA, an endogenous ambiphilic bile acid, can inhibit unfolded protein response dysfunction and ameliorate ER stress. TUDCA administration attenuates HDM-induced ER stress, airway inflammation, mucus metaplasia, airway remodeling, and methacholine-induced AHR[2].
Animal Research Animal Models House dust mite-induced allergic airway disease mouse model (background: C57BL/6 NJ mice)
Dosages 0.5, 1, and 5 mg/kg body wt
Administration via the nasopharynx
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05753852 Recruiting
Amyotrophic Lateral Sclerosis
Humanitas Mirasole SpA|University of Ulm|University of Sheffield|University Hospital Tours|KU Leuven|UMC Utrecht|University of Dublin Trinity College|Bruschettini S.r.l.|Istituto Superiore di Sanità|Motor Neurone Disease Association
October 25 2021 Phase 3
NCT04114292 Unknown status
Ulcerative Colitis
Washington University School of Medicine|Crohn''s and Colitis Foundation
January 17 2019 Phase 1
NCT01899703 Completed
Cholestasis Intrahepatic
GlaxoSmithKline
March 10 2014 Phase 2

Chemical Information & Solubility

Molecular Weight 499.70 Formula

C26H45NO6S

CAS No. 14605-22-2 SDF Download Tauroursodeoxycholic Acid (TUDCA) SDF
Smiles CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 100 mg/mL ( (200.12 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : 50 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) supplier | purchase Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) cost | Tauroursodeoxycholic Acid (TUDCA) manufacturer | order Tauroursodeoxycholic Acid (TUDCA) | Tauroursodeoxycholic Acid (TUDCA) distributor